精品国产精品免费在线观看|亚洲一级高清在线观看|亚洲乱码尤物193yw|亚洲综合狠狠99婷婷

      Oncology And Therapy
      • 數(shù)據(jù)庫收錄SCIE
      • 年發(fā)文量26

      Oncology And Therapy

      期刊中文名:腫瘤學(xué)與治療ISSN:2366-1070E-ISSN:2366-1089

      該雜志國(guó)際簡(jiǎn)稱:ONCOL THER,是由出版商Adis, Springer Healthcare出版的一本致力于發(fā)布--研究新成果的的專業(yè)學(xué)術(shù)期刊。主要發(fā)表刊登有創(chuàng)見的學(xué)術(shù)論文文章、行業(yè)最新科研成果,扼要報(bào)道階段性研究成果和重要研究工作的最新進(jìn)展,選載對(duì)學(xué)科發(fā)展起指導(dǎo)作用的綜述與專論,促進(jìn)學(xué)術(shù)發(fā)展,為廣大讀者服務(wù)。該刊是一本國(guó)際優(yōu)秀雜志,在國(guó)際上有很高的學(xué)術(shù)影響力。

      基本信息:
      期刊簡(jiǎn)稱:ONCOL THER
      是否OA:開放
      是否預(yù)警:
      Gold OA文章占比:100.00%
      出版信息:
      出版地區(qū):United Kingdom
      出版周期:2 issues per year
      出版語言:English
      出版商:Adis, Springer Healthcare
      評(píng)價(jià)信息:
      JCR分區(qū):Q2
      影響因子:3.2
      CiteScore:3.4
      雜志介紹 JCR分區(qū) CiteScore 投稿經(jīng)驗(yàn)

      雜志介紹

      Oncology And Therapy雜志介紹

      《Oncology And Therapy》是一本以English為主的開放獲取國(guó)際優(yōu)秀期刊,中文名稱腫瘤學(xué)與治療,本刊主要出版、報(bào)道領(lǐng)域的研究動(dòng)態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗(yàn)和科研成果,介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展,探討行業(yè)發(fā)展的思路和方法,以促進(jìn)學(xué)術(shù)信息交流,提高行業(yè)發(fā)展。該刊已被國(guó)際權(quán)威數(shù)據(jù)庫SCIE收錄,為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動(dòng)作用,也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為3.2,最新CiteScore 指數(shù)為3.4。

      英文介紹

      Oncology And Therapy雜志英文介紹

      oncology And Therapy Is An International, Peer Reviewed, Rapid-publication (peer Review In 2 Weeks, Published 3–4 Weeks From Acceptance) Journal Dedicated To The Publication Of High-quality Pre-clinical, Clinical (all Phases), Observational, Real-world, And Health Outcomes Research Around The Discovery, Development, And Use Of Therapeutics And Interventions (including Devices) Across All Therapeutic Areas. Studies Relating To Diagnostics And Diagnosis, Pharmacoeconomics, Public Health, Epidemiology, Quality Of Life, And Patient Care, Management, And Education Are Also Encouraged.

      the Journal Is Of Interest To A Broad Audience Of Healthcare Professionals And Publishes Original Research, Reviews, Communications And Letters. The Journal Is Read By A Global Audience And Receives Submissions From All Over The World. Oncology And Therapy Will Consider All Scientifically Sound Research Be It Positive, Confirmatory Or Negative Data. Submissions Are Welcomed Whether They Relate To An International And/or A Country-specific Audience, Something That Is Crucially Important When Researchers Are Trying To Target More Specific Patient Populations. This Inclusive Approach Allows The Journal To Assist In The Dissemination Of All Scientifically And Ethically Sound Research.

      JCR分區(qū)(2023-2024年最新版)

      Oncology And Therapy雜志 JCR分區(qū)信息

      按JIF指標(biāo)學(xué)科分區(qū)
      學(xué)科:ONCOLOGY
      收錄子集:ESCI
      分區(qū):Q2
      排名:129 / 322
      百分位:

      60.1%

      按JCI指標(biāo)學(xué)科分區(qū)
      學(xué)科:ONCOLOGY
      收錄子集:ESCI
      分區(qū):Q3
      排名:225 / 322
      百分位:

      30.28%

      JCR分區(qū):JCR分區(qū)來自科睿唯安公司,JCR是一個(gè)獨(dú)特的多學(xué)科期刊評(píng)價(jià)工具,為唯一提供基于引文數(shù)據(jù)的統(tǒng)計(jì)信息的期刊評(píng)價(jià)資源。每年發(fā)布的JCR分區(qū),設(shè)置了254個(gè)具體學(xué)科。JCR分區(qū)根據(jù)每個(gè)學(xué)科分類按照期刊當(dāng)年的影響因子高低將期刊平均分為4個(gè)區(qū),分別為Q1、Q2、Q3和Q4,各占25%。JCR分區(qū)中期刊的數(shù)量是均勻分為四個(gè)部分的。

      CiteScore 評(píng)價(jià)數(shù)據(jù)(2024年最新版)

      Oncology And Therapy雜志CiteScore 評(píng)價(jià)數(shù)據(jù)

      • CiteScore 值:3.4
      • SJR:0.898
      • SNIP:0.883
      學(xué)科類別 分區(qū) 排名 百分位
      大類:Medicine 小類:Oncology Q3 236 / 404

      41%

      歷年影響因子和期刊自引率

      投稿經(jīng)驗(yàn)

      Oncology And Therapy雜志投稿經(jīng)驗(yàn)

      該雜志是一本國(guó)際優(yōu)秀雜志,在國(guó)際上有較高的學(xué)術(shù)影響力,行業(yè)關(guān)注度很高,已被國(guó)際權(quán)威數(shù)據(jù)庫SCIE收錄,該雜志在綜合專業(yè)領(lǐng)域?qū)I(yè)度認(rèn)可很高,對(duì)稿件內(nèi)容的創(chuàng)新性和學(xué)術(shù)性要求很高,作為一本國(guó)際優(yōu)秀雜志,一般投稿過審時(shí)間都較長(zhǎng),投稿過審時(shí)間平均 6 Weeks ,如果想投稿該刊要做好時(shí)間安排。版面費(fèi)不祥。該雜志近兩年未被列入預(yù)警名單,建議您投稿。如您想了解更多投稿政策及投稿方案,請(qǐng)咨詢客服。

      免責(zé)聲明

      若用戶需要出版服務(wù),請(qǐng)聯(lián)系出版商。